AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-2749475_ITM" title="Facts and information about Adjunct diabetes Rx. (Products).">Adjunct diabetes Rx. (Products).</a>
Close
Set up an RSS feed that alerts you when new articles from OB GYN News are available.
Frequently asked questions about RSS feeds
Adjunct diabetes Rx. (Products).
Avandamet (rosiglitazone maleate/metformin) is approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus, who are already treated with a combination of rosiglitazone and metformin, or who are ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Rosiglitazone has lower treatment failure rate.(Endocrinology)
- Magazine article from: Internal Medicine News Tucker, Miriam E. January 1, 2007 700+ words
...assigned to receive initial daily dosages of 4 mg rosiglitazone, 500 mg metformin, or 2.5 mg glyburide. For each drug...up to twice-daily dosages each of 4 mg rosiglitazone, 1,000 mg metformin, and 7.5 mg glyburide. Dosages were...
- Rosiglitazone reduces CRP, atherosclerosis in diabetics.(Cardiovascular...
- Magazine article from: Internal Medicine News Zoler, Mitchel L. January 15, 2006 700+ words
...sulfonylurea drug. Patients were randomized to treatment on an open-label basis to either 4 mg rosiglitazone (Avandia) daily or 850 mg metformin (Glucophage) twice daily. The randomization was stratified to assign patients with similar...
- Rosiglitazone reduces CRP and carotid atherosclerosis.(Metabolic...
- Magazine article from: Family Practice News Zoler, Mitchel L. January 15, 2006 700+ words
...sulfonylurea drug. Patients were randomized to treatment on an open-label basis to either 4 mg rosiglitazone (Avandia) daily or 850 mg metformin (Glucophage) twice daily. The randomization was stratified to assign patients with similar...
- Vildagliptin lowers [A.sub.1c] levels without causing weight gain.(News)
- Magazine article from: Internal Medicine News Tucker, Miriam E. November 15, 2006 700+ words
...in 50-mg doses twice daily to 526 patients, and 1000 mg metformin was given twice daily to 254 patients. Hemoglobin [A...receive 100 mg/day vildagliptin while 238 patients took 8 mg rosiglitazone daily. The two agents decreased [A.sub.1c] levels...
- Interim Analysis of Long-Term Data with ONGLYZA[TM] (saxagliptin) When Added to...
- Press release article from: Business Wire June 6, 2009 700+ words
...four separate treatment arms: saxagliptin 2.5 mg + metformin 1500 to 2500 mg/day (n=192), saxagliptin 5 mg + metformin 1500 to 2500 mg/day (n=191), saxagliptin 10 mg + metformin 1500 to 2500 mg/day (n=181), or placebo...
- Interim Analysis of Long-Term Data with ONGLYZA[TM] saxagliptin When Added to...
- Newspaper article from: Obesity & Diabetes Week June 22, 2009 700+ words
...four separate treatment arms: saxagliptin 2.5 mg + metformin 1500 to 2500 mg/day (n=192), saxagliptin 5 mg + metformin 1500 to 2500 mg/day (n=191), saxagliptin 10 mg + metformin 1500 to 2500 mg/day (n=181), or placebo...
- ONGLYZA saxagliptin With Metformin as Initial Combination Therapy Significantly...
- Newspaper article from: Obesity & Diabetes Week September 22, 2008 700+ words
...separate treatment arms: saxagliptin 5 mg + metformin 500 mg (n=320), saxagliptin 10 mg + metformin 500 mg (n=323), saxagliptin 10...Week 1 to Week 5, in the saxagliptin 5 mg + metformin, saxagliptin 10 mg + metformin and...
- Reports from Bristol-Myers Squibb Company advance knowledge in type 2 diabetes.
- Newspaper article from: Obesity & Diabetes Week June 29, 2009 700+ words
...were randomized to receive saxagliptin 5 mg + metformin 500 mg, saxagliptin 10 mg + metformin 500 mg, saxagliptin 10 mg + placebo or...2000 mg/day maximum in the saxagliptin 5 mg + metformin, saxagliptin 10 mg + metformin and metformin...